Literature DB >> 11858726

Production and purification of a recombinant Staphylococcal enterotoxin B vaccine candidate expressed in Escherichia coli.

J Daniel Coffman1, Jianwei Zhu, John M Roach, Sina Bavari, Robert G Ulrich, Steven L Giardina.   

Abstract

An attenuated, recombinant form of Staphylococcus enterotoxin B (rSEB) was overexpressed in Escherichia coli under transcriptional control of the T7 promoter. The 28-kDa rSEB was partially purified from soluble, intracellular protein by tangential flow filtration and differential ammonium sulfate precipitation. The intermediate product was then further purified using low-pressure liquid chromatography including hydrophobic interaction, cation exchange, and size-exclusion matrices. The final vialed product was >95% pure as determined by Coomassie blue-stained sodium dodecyl sulfate-polyacrylamide gel electrophoresis, high-pressure size-exclusion chromatography, and capillary zonal electrophoresis. The endotoxin level was <0.6 EU/mg. Final estimated yield of purified rSEB was 147 mg/L of starting culture. Purified rSEB was stable, elicited an immune response in mice, and protected mice against a lethal challenge with the native toxin. Copyright 2002 Elsevier Science (USA).

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11858726     DOI: 10.1006/prep.2001.1556

Source DB:  PubMed          Journal:  Protein Expr Purif        ISSN: 1046-5928            Impact factor:   1.650


  12 in total

1.  Synthetic human monoclonal antibodies toward staphylococcal enterotoxin B (SEB) protective against toxic shock syndrome.

Authors:  Hatice Karauzum; Gang Chen; Laura Abaandou; Mahta Mahmoudieh; Atefeh R Boroun; Sergey Shulenin; V Sathya Devi; Eric Stavale; Kelly L Warfield; Larry Zeitlin; Chad J Roy; Sachdev S Sidhu; M Javad Aman
Journal:  J Biol Chem       Date:  2012-05-29       Impact factor: 5.157

2.  Persistence of zinc-binding bacterial superantigens at the surface of antigen-presenting cells contributes to the extreme potency of these superantigens as T-cell activators.

Authors:  Dorothy D Pless; Gordon Ruthel; Emily K Reinke; Robert G Ulrich; Sina Bavari
Journal:  Infect Immun       Date:  2005-09       Impact factor: 3.441

3.  Attenuation of massive cytokine response to the staphylococcal enterotoxin B superantigen by the innate immunomodulatory protein lactoferrin.

Authors:  J L Hayworth; K J Kasper; M Leon-Ponte; C A Herfst; D Yue; W C Brintnell; D M Mazzuca; D E Heinrichs; E Cairns; J Madrenas; D W Hoskin; J K McCormick; S M M Haeryfar
Journal:  Clin Exp Immunol       Date:  2009-07       Impact factor: 4.330

4.  Safety and Immunogenicity of a Parenterally Administered, Structure-Based Rationally Modified Recombinant Staphylococcal Enterotoxin B Protein Vaccine, STEBVax.

Authors:  Wilbur H Chen; Marcela F Pasetti; Rajan P Adhikari; Holly Baughman; Robin Douglas; Jill El-Khorazaty; Nancy Greenberg; Frederick W Holtsberg; Grant C Liao; Mardi K Reymann; Xiaolin Wang; Kelly L Warfield; M Javad Aman
Journal:  Clin Vaccine Immunol       Date:  2016-12-05

5.  Oral vaccine formulations stimulate mucosal and systemic antibody responses against staphylococcal enterotoxin B in a piglet model.

Authors:  Tiffany K Inskeep; Chad Stahl; Jack Odle; Judy Oakes; Laura Hudson; Kenneth L Bost; Kenneth J Piller
Journal:  Clin Vaccine Immunol       Date:  2010-06-16

6.  Nasal immunity to staphylococcal toxic shock is controlled by the nasopharynx-associated lymphoid tissue.

Authors:  Stefan Fernandez; Emily D Cisney; Shannan I Hall; Robert G Ulrich
Journal:  Clin Vaccine Immunol       Date:  2011-02-16

7.  Sublethal staphylococcal enterotoxin B challenge model in pigs to evaluate protection following immunization with a soybean-derived vaccine.

Authors:  Laura C Hudson; Brynn S Seabolt; Jack Odle; Kenneth L Bost; Chad H Stahl; Kenneth J Piller
Journal:  Clin Vaccine Immunol       Date:  2012-10-31

8.  Interleukin-15 increases vaccine efficacy through a mechanism linked to dendritic cell maturation and enhanced antibody titers.

Authors:  Kamal U Saikh; Teri L Kissner; Steven Nystrom; Gordon Ruthel; Robert G Ulrich
Journal:  Clin Vaccine Immunol       Date:  2007-11-28

9.  Novel structurally designed vaccine for S. aureus α-hemolysin: protection against bacteremia and pneumonia.

Authors:  Rajan P Adhikari; Hatice Karauzum; Jawad Sarwar; Laura Abaandou; Mahta Mahmoudieh; Atefeh R Boroun; Hong Vu; Tam Nguyen; V Sathya Devi; Sergey Shulenin; Kelly L Warfield; M Javad Aman
Journal:  PLoS One       Date:  2012-06-06       Impact factor: 3.240

10.  Vaccine based on a ubiquitous cysteinyl protease and streptococcal pyrogenic exotoxin A protects against Streptococcus pyogenes sepsis and toxic shock.

Authors:  Robert G Ulrich
Journal:  J Immune Based Ther Vaccines       Date:  2008-10-31
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.